NO991533L - NMDA (N-metyl-D-aspartat) antagonister - Google Patents

NMDA (N-metyl-D-aspartat) antagonister

Info

Publication number
NO991533L
NO991533L NO991533A NO991533A NO991533L NO 991533 L NO991533 L NO 991533L NO 991533 A NO991533 A NO 991533A NO 991533 A NO991533 A NO 991533A NO 991533 L NO991533 L NO 991533L
Authority
NO
Norway
Prior art keywords
nmda
aspartate
antagonists
methyl
Prior art date
Application number
NO991533A
Other languages
English (en)
Other versions
NO991533D0 (no
NO314080B1 (no
Inventor
Boyd L Harrison
Raymond S Gross
Bruce M Baron
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of NO991533D0 publication Critical patent/NO991533D0/no
Publication of NO991533L publication Critical patent/NO991533L/no
Publication of NO314080B1 publication Critical patent/NO314080B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19991533A 1996-09-30 1999-03-29 NMDA (N-metyl-D-aspartat) antagonister, farmasöytisk preparat inneholdendedisse og anvendelse derav for fremstilling av et medikament NO314080B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72317596A 1996-09-30 1996-09-30
PCT/US1997/014486 WO1998014427A1 (en) 1996-09-30 1997-08-18 Nmda (n-methyl-d-aspartate) antagonists

Publications (3)

Publication Number Publication Date
NO991533D0 NO991533D0 (no) 1999-03-29
NO991533L true NO991533L (no) 1999-05-28
NO314080B1 NO314080B1 (no) 2003-01-27

Family

ID=24905175

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991533A NO314080B1 (no) 1996-09-30 1999-03-29 NMDA (N-metyl-D-aspartat) antagonister, farmasöytisk preparat inneholdendedisse og anvendelse derav for fremstilling av et medikament

Country Status (18)

Country Link
EP (1) EP0929521B1 (no)
JP (1) JP2001501221A (no)
KR (1) KR20000048715A (no)
CN (1) CN1139572C (no)
AR (1) AR009374A1 (no)
AT (1) ATE309215T1 (no)
AU (1) AU732997B2 (no)
BR (1) BR9712144A (no)
CA (1) CA2266556C (no)
DE (1) DE69734594T2 (no)
DK (1) DK0929521T3 (no)
HU (1) HUP0000882A3 (no)
IL (1) IL129187A0 (no)
NO (1) NO314080B1 (no)
NZ (1) NZ334343A (no)
TW (1) TW492958B (no)
WO (1) WO1998014427A1 (no)
ZA (1) ZA978602B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053849A1 (en) * 1999-06-16 2001-12-20 Mary Jeanne Kreek Plural biological sample arrays, and preparation and uses thereof
IL152473A0 (en) 2000-04-28 2003-05-29 Sloan Kettering Inst Cancer Topical anesthetic/opioid formulations and uses thereof
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US7820688B2 (en) 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
US20030162825A1 (en) * 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
CN101896457A (zh) * 2007-10-22 2010-11-24 幽兰研究实验室有限公司 组蛋白脱乙酰基酶抑制剂
IN2012DN06631A (no) 2010-02-16 2015-10-23 Pfizer
US11613547B2 (en) 2019-07-08 2023-03-28 University Of Health Sciences & Pharmacy In St. Louis G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2088011T3 (es) * 1990-07-16 1996-08-01 Merrell Pharma Inc Antagonistas de aminoacidos excitadores.
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
HU216633B (hu) * 1993-05-27 1999-07-28 Merrel Pharmaceuticals Inc. NMDA-antagonista hatású 3-(indol-3-il)-propénsav-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
DE69734594D1 (en) 2005-12-15
AU732997B2 (en) 2001-05-03
ZA978602B (en) 1998-03-30
BR9712144A (pt) 1999-08-31
DE69734594T2 (de) 2006-07-06
CA2266556C (en) 2007-11-06
HUP0000882A3 (en) 2001-04-28
CN1232452A (zh) 1999-10-20
NO991533D0 (no) 1999-03-29
DK0929521T3 (da) 2006-03-27
IL129187A0 (en) 2000-02-17
CA2266556A1 (en) 1998-04-09
NO314080B1 (no) 2003-01-27
HUP0000882A2 (hu) 2000-09-28
AR009374A1 (es) 2000-04-12
EP0929521A1 (en) 1999-07-21
ATE309215T1 (de) 2005-11-15
JP2001501221A (ja) 2001-01-30
TW492958B (en) 2002-07-01
AU4071897A (en) 1998-04-24
NZ334343A (en) 2001-01-26
CN1139572C (zh) 2004-02-25
KR20000048715A (ko) 2000-07-25
EP0929521B1 (en) 2005-11-09
WO1998014427A1 (en) 1998-04-09

Similar Documents

Publication Publication Date Title
DK1009732T3 (da) 1-Amino-alkylcyclohexan NMDA receptor antagonister
DE69525857T2 (de) Östrogen-agonisten/antagonisten
EE9600186A (et) Neurokiniini (tahhüülkiniini) antagonistid
DE69830854D1 (de) Mehrfaches testverfahren
DE69622751D1 (de) Arbeitsplatz
DE69726660D1 (de) Projektionsvorrichtung
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
DK0929521T3 (da) NMDA-antagonister (N-methyl-D-aspartat-antagnonister)
DE29612584U1 (de) Adapterbauteil
DE29604276U1 (de) Prüfgerät
DE29602238U1 (de) Prüfgerät
DE69015745D1 (de) NMDA-Antagonisten.
DE29711173U1 (de) Adapter
KR970702876A (ko) 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists)
KR950027351U (ko) 반목 항타장치
DE29707827U1 (de) Arretiervorrichtung für einen Ausziehtisch
SE9700316D0 (sv) Strömmätare
DE29722804U1 (de) Prüfvorrichtung
KR960006324U (ko) 프로빙 시간단축 쏘소자
DE29719617U1 (de) Gewindeadapter
KR970047433U (ko) 어댑터
DE29713134U1 (de) Adapter
FI974114A0 (fi) Skorstenshatt (regntak)